BRAF and melanoma: This 3-year analysis showed that in Chinese patients with unresectable or metastatic BRAF V600-mutant melanoma, median OS and 3-year OS rate were 17.6 months and 23%, respectively, after treatment with dabrafenib plus trametinib.